American Funds Growth and Income Portfolio Class F-3 (GAIHX) kopieguldījumu fonda cena un jaunumi

SākumlapaGAIHX • Ieguldījumu fonds

American Funds Growth and Income Portfolio Class F-3

21,83 $

12. febr. · USD · MUTF · Atruna

American Funds Growth and Income Portfolio Class ABLE-F-2

21,88 $

CGLGX0,86%

American Funds Growth and Income Portfolio Class R-6

21,88 $

RGNGX0,86%

American Funds Growth and Income Portfolio Class 529-F-3

21,82 $

FGIIX0,86%

American Funds Growth and Income Portfolio Class R-2E

21,71 $

RBEGX0,87%

American Funds Growth and Income Portfolio Class ABLE-A

21,86 $

CGNGX0,86%

American Funds Growth and Income Portfolio Class R-5E

21,78 $

RGQFX0,86%

American Funds Growth and Income Portfolio Class R-1

21,65 $

RGNAX0,87%

American Funds Growth and Income Portfolio Class C

21,63 $

GAITX0,87%

American Funds Growth and Income Portfolio Class R-3

21,70 $

RAICX0,87%

American Funds Growth and Income Portfolio Class A

21,81 $

GAIOX0,86%

Ieguldījumu fonds

Slēgšanas kurss

22,02 $

Peļņa no gada sākuma

2,44%

Izdevumu koeficients

0,34%

Kategorija

Aggressive Allocation

Morningstar vērtējums

Neto aktīvi

420,48 milj. USD

Peļņa

1,94%

Komisija

Ieviešanas datums

2017. gada 27. janv.

Tirgus ziņas

MarketWatch

pirms 13 stundām

Dow ends below 50,000 threshold for first time since Friday as AI fears spark wider stock selloff

World shares mixed after sharp Wall Street losses on AI-related worries

Reuters

pirms 2 dienām

Wall Street ends muted after strong jobs data nibbles at Fed rate cut bets

FinancialContent

pirms 13 stundām

FinancialContent - $400M to $1B: IQSTEL (Nasdaq: IQST) Builds Momentum in High-Growth Fintech & Cybersecurity. Expanding Profitability with Growth in Fintech and Cybersecurity

If EPS Growth Is Important To You, Linde (NASDAQ:LIN) Presents An Opportunity

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

ASBP

2,96%